Revvity Reports $729 Million in Third-Quarter Revenue as Growth Reaccelerates

The Tip Desk · November 3, 2026 · 2 min read

Pro forma revenue growth reached 7% in the third quarter and the company now forecasts about $2.86 billion of full-year pro forma revenue.

Revvity, Inc. (RVTY) reported third-quarter 2026 revenue of $729 million as pro forma growth reaccelerated from the second quarter.

The health-science solutions company said pro forma revenue was $710 million, up 7% from a year earlier, and pro forma organic revenue growth was 7%. That compared with 4% pro forma revenue growth and 3% pro forma organic growth in the second quarter. Reported revenue was $729 million, versus $699 million a year earlier.

GAAP earnings from continuing operations were $0.56 a share, compared with $0.41 a year earlier. Adjusted earnings from continuing operations were $1.38 a share, versus $1.18 a year earlier. GAAP operating income from continuing operations was $95 million, and GAAP operating profit margin was 13.1%, up from 11.7% a year earlier. Adjusted operating income was $209 million, and the adjusted operating profit margin was 28.7%.

President and Chief Executive Officer Prahlad Singh said the quarter showed “broad-based growth and strong execution” that drove results “meaningfully ahead of our expectations.”

Life Sciences was the larger of the two reportable segments. Third-quarter revenue was $380 million, compared with $343 million a year earlier. Pro forma revenue increased 11% and pro forma organic revenue increased 9%. Adjusted operating income in the segment was $119 million, and the adjusted operating profit margin was 31.5%, up from 29.5% a year earlier.

Diagnostics revenue was $349 million, compared with $356 million a year earlier. Pro forma revenue increased 4% and pro forma organic revenue increased 5%. Adjusted operating income was $104 million, and the adjusted operating profit margin was 29.9%, up from 25.1% a year earlier.

The company reiterated that it entered a definitive agreement to divest its Immunodiagnostics business in China, which represented about 6% of 2025 revenue. The transaction is expected to close by the end of 2027, subject to customary closing conditions and regulatory approvals. Results are presented on a reported and pro forma basis; forward-looking guidance is on a pro forma basis only and excludes China IDX.

For the full year 2026, on a pro forma basis, Revvity now forecasts total revenue of approximately $2.86 billion, pro forma organic revenue growth of approximately 5%, and pro forma adjusted earnings of $5.40 to $5.45 a share. The company said it will host an Investor Day on November 13, 2026.